Healthcare - Biotechnology - NASDAQ - US
$ 2.27
-7.72 %
$ 476 M
Market Cap
-1.46
P/E
CASH FLOW STATEMENT
-238 M
OPERATING CASH FLOW
163 M
INVESTING CASH FLOW
95.7 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Allogene Therapeutics, Inc.
| Net Income | -327 M |
| Depreciation & Amortization | 14.2 M |
| Capital Expenditures | -1.52 M |
| Stock-Based Compensation | 66 M |
| Change in Working Capital | -15.3 M |
| Others | 16.9 M |
| Free Cash Flow | -239 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | |
|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||
| Net Income | (327.3) | (332.6) | (257.0) | (250.2) | (184.6) | (211.5) | 24 K |
| Depreciation & Amortization | 14.2 | 14.3 | 10.5 | 7.6 | 5.0 | 1.5 | 0 |
| Deferred Income Tax | 0 | 8.1 | 10.4 | 4.4 | (0.3) | (0.1) | 0 |
| Stock Based Compensation | 66.0 | 83.6 | 80.8 | 65.3 | 46.1 | 18.6 | 0 |
| Other Operating Activities | 24.7 | 2.4 | 2.6 | 4.0 | 3.4 | 134.8 | 0 |
| Change in Working Capital | (15.3) | 3.7 | (32.1) | 53.9 | (6.9) | 12.1 | 24 K |
| Cash From Operations | (237.7) | (220.5) | (184.8) | (115.1) | (137.3) | (44.7) | 0 |
| INVESTING CASH FLOW | |||||||
| Capital Expenditures | (1.5) | (5.2) | (21.4) | (66.0) | (50.8) | (3.2) | 0 |
| Other Items | 164.8 | 111.3 | 185.1 | (439.2) | 214.9 | (629.6) | 0 |
| Cash From Investing Activities | 163.3 | 106.2 | 163.7 | (505.1) | 164.1 | (632.8) | 0 |
| FINANCING CASH FLOW | |||||||
| Common Stock Repurchased | 0 | 2.5 | 3.6 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 0 | 116.8 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 4.6 | 3.0 | 12.0 | 11.7 | 4.7 | 953.6 | 0 |
| Cash From Financing Activities | 95.7 | 3.0 | 12.0 | 633.6 | 59.0 | 771.2 | 0 |
| CHANGE IN CASH | |||||||
| Net Change In Cash | 21.3 | (111.4) | (9.2) | 13.4 | 85.7 | 93.7 | 0 |
| FREE CASH FLOW | |||||||
| Free Cash Flow | (239.2) | (225.7) | (206.3) | (181.1) | (188.1) | (47.9) | 0 |